Global TROP2 Antibody Market Opportunity & Clinical Trials Insight 2030

Global TROP2 Antibody Market Opportunity & Clinical Trials Insight 2030 Report Highlights & Inclusions:

• TROP2 Antibody Global & Regional Sales Insights
• Global TROP2 Antibody Market Opportunity: > US$ 4 Billion
• Global TROP2 Antibody Market Witnessed 23% Growth In 2024
• TROP2 Therapeutic Market Trends By Region & Indications
• Approved Drugs Dosage, Price & Sales Insight: Global & Regional
• TROP2 Antibodies Clinical Trials Insight By Company, Country, Indication & Phase 
• Insight On More Than 40 Antibodies In Clinical Trials

TROP2 (Trophoblast cell surface antigen 2) has emerged as a significant therapeutic target in the fight against various cancers. This Type-I transmembrane glycoprotein is encoded by the TACSTD2 gene and plays a key role in regulating cell signaling pathways, particularly by modulating EpCAM-induced signaling. TROP2 is overexpressed in numerous epithelial cancers, leading to an increased tumor growth rate and metastasis. Moreover, its overexpression is associated with poor prognosis, particularly in solid tumors, making it an ideal target for targeted cancer therapies. 

As traditional cancer therapies often come with limitations, such as severe side effects and ineffectiveness in certain patient populations, the need for new approaches is growing. The targeted therapy segment has seen significant growth in recent years, with a focus on novel cancer antigens, receptors, and biomarkers. TROP2-targeted therapies represent one such promising avenue, demonstrating high safety and therapeutic efficacy across several major cancer types. These therapies aim to deliver cytotoxic drugs directly to tumor sites, potentially reducing the adverse effects associated with traditional treatments.

As of February 2025, three TROP2-targeted therapies have been approved for clinical use, marking a major milestone in the commercialization of this approach. The first of these is Trodelvy (sacituzumab govitecan), which received accelerated FDA approval in 2020 for the treatment of metastatic triple-negative breast cancer (TNBC). Trodelvy was later granted full approval in 2021 and expanded its indication in 2023 to include HR+/HER2- metastatic breast cancer. Another significant approval came in late 2024, when Sacituzumab Tirumotecan (SKB264) was granted approval in China for TNBC. Additionally, Datroway (dato-dxd), an ADC developed by AstraZeneca and Daiichi Sankyo, was approved for breast cancer in the US and Japan. These approvals highlight the growing role of TROP2-targeted therapies in oncology and the expanding market potential.

The commercial success of Trodelvy has been a key driver of the TROP2-targeted therapy market. The drug’s success has spurred additional research and investment into the TROP2 pathway, with several pharmaceutical companies and biotechnology firms intensifying their focus on this target. Major players in the TROP2 space include Gilead, AstraZeneca, Daiichi Sankyo, Klus Pharma, Biothera, Escugen Biotechnology, and Shanghai Junshi Biosciences. Many of these companies have incorporated TROP2-targeted therapies into their clinical pipelines, with numerous candidates in early and mid-stages of development.

Several TROP2-targeted therapies are currently in clinical trials, with investigational drugs such as OBI-992, JS108, ESG-401 and SHR-A1921 showing promise. These candidates, including monoclonal antibodies, antibody-drug conjugates (ADCs), immunotherapies and cell therapies, aim to expand the therapeutic options available to patients with difficult-to-treat cancers. As more of these therapies move through the pipeline, the TROP2-targeted therapy market is expected to experience substantial growth.

In terms of market dynamics, the segment is expected to continue its expansion. Driven by the clinical success of Trodelvy, increasing investments, and a growing pipeline of TROP2-targeted therapies, this market is poised for significant growth. The therapeutic potential of TROP2-targeted treatments is vast, with applications for various cancer types, including TNBC, urothelial carcinoma, and other solid tumors. As more therapies are approved and enter the market, the commercial side of TROP2-targeted therapies will see continued development, offering new opportunities for both patients and pharmaceutical companies.

In conclusion, TROP2 as a therapeutic target holds considerable promise in revolutionizing cancer treatment. With three drugs already approved and many more in the pipeline, TROP2-targeted therapies are positioned to become a cornerstone of targeted cancer therapies. The growing interest from major pharmaceutical companies, along with the increasing number of investigational drugs, signals a bright future for this therapeutic approach in the oncology market.